<DOC>
	<DOCNO>NCT00445575</DOCNO>
	<brief_summary>This trial intend test efficacy oral bisphosphonate ( risedronate ) decrease bone pain improve radiological aspect fibrous dysplasia bone .</brief_summary>
	<brief_title>Effect Risedronate Bone Morbidity Fibrous Dysplasia Bone</brief_title>
	<detailed_description>In open pilot study , suggest bisphosphonates may alleviate bone pain help decrease surface osteolytic lesion patient fibrous dysplasia bone ( FD ) . So , randomize placebo control trial , test hypothesis bisphosphonate risedronate reduces bone pain patient FD ( study I , one year duration ) decrease osteolytic lesion ( study II , three year duration ) . Patients take risedronate 2 month course , every 6 month match placebo . Dosage : 30mg tablet/day adult 5mg tablet x 2,4 accord age weight child . All participant receive calcium vitamin D. All patient renal phosphate waste receive oral phosphate supplement .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Fibrous Dysplasia Bone</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>Study I : patient FD , bone pain intensity 3 visual analogical scale 0 10 Study II : patient FD least one osteolytic lesion current bone pain patient &lt; 8 year old disease affect bone metabolism patient malignant disease condition likely reduce life expectancy le 3 year patient history significant upper gastrointestinal disorder renal failure ( creatinine clearance &lt; 25 ml/mn ) severe liver disease history iritis uveitis rickets osteomalacia allergy bisphosphonates pregnancy lactation prior treatment bisphosphonate laboratory abnormality may consider clinically significant trial physician</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>fibrous dysplasia bone</keyword>
	<keyword>Mac Cune Albright syndrome</keyword>
	<keyword>bisphosphonates</keyword>
	<keyword>risedronate</keyword>
</DOC>